INSULET CORP (PODD)
US45784P1012 - Common Stock
Wednesday Sector Laggards: Healthcare, Services
What's going on in today's session: S&P500 movers
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.
Tuesday's session: top gainers and losers in the S&P500 index
Tuesday Sector Leaders: Materials, Healthcare
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
Why NASDAQ:PODD Is a Promising High-Growth Stock in the Midst of Consolidation.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock?
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
7 Stable Stocks for 50% Returns by Early 2025
These 7 stable stocks also offer 50% returns according to analysts according to analysts tasked with following their respective industries.
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
Wednesday Sector Laggards: Healthcare, Utilities
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
Tuesday Sector Laggards: Technology & Communications, Healthcare
Wednesday Sector Laggards: Technology & Communications, Healthcare
PODD July 2025 Options Begin Trading
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
Is It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?
A handful of large-cap stocks are now on sale. The discount, however, doesn't necessarily make them worth buying.
Kinsale Capital Group Moves Up In Market Cap Rank, Passing Insulet
Insulet Enters Oversold Territory (PODD)
Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M (NASDAQ:PODD)
Insulet press release (NASDAQ:PODD): Q4 Non-GAAP EPS of $1.40 beats by $0.74.Revenue of $509.8M (+37.9% Y/Y) beats by $48.74M.Total Omnipod revenue of...
Notable Thursday Option Activity: NEM, PODD, INTU
Commit To Purchase Insulet At $140, Earn 8.7% Annualized Using Options
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
Insulet gets CE Mark for Ominipod 5 with FreeStyle Libre 2 sensor (NASDAQ:PODD)
Insulet (PODD) has received European approval for its Omnipod 5 insulin delivery system integrated with Abbott's (ABT) FreeStyle Libre 2 Plus sensor for type 1 diabetes.
